On 6 May 2026, the Philippine Food and Drug Administration (FDA) issued FDA Advisory No. 2026-0594,
formally launching the new “eSumbong” complaint and reporting system, integrated into the newly redesigned FDA website. The system is the FDA’s official centralized platform for receiving product- and establishment-related complaints and supporting market surveillance and enforcement, marking another important step in the Philippines’ compliance oversight of medical devices and other regulated health products.
1. Background: Replacing the eReport Mechanism
According to the advisory, eSumbong is integrated into the FDA’s new website, and the previous eReport mechanism and its email addresses have been discontinued with immediate effect. From the date of the advisory, eSumbong is the FDA’s only official channel for the relevant categories of complaints and reports.
Notably, the Philippine FDA recently announced a five-year strategic development plan to address long-standing structural problems such as case backlogs, staff shortages and outdated digital infrastructure. The launch of eSumbong can be seen as one concrete measure within this overall digital reform plan.
2. Five Categories of Reports Accepted
According to the advisory, eSumbong strictly accepts only the following five categories of reports, routed to the corresponding internal FDA units:
-
Counterfeit and Violative Product Reporting: health products that are counterfeit, unregistered, adulterated or falsely labeled
-
Unlicensed Establishments Reporting: complaints about premises, warehouses or outlets operating without an FDA License to Operate (LTO)
-
Anti-Corruption Complaints: misconduct, solicitation of bribes or corruption by FDA personnel (including contractual staff and consultants) in the course of their duties, handled specifically by the Office of the Director General
-
Application-Related Complaints: formal complaints about errors in the approval process, systemic failures, or processing beyond the time limits set in the Citizen’s Charter
-
Product-Related Complaints: adverse drug reactions, product quality defects or safety issues arising from the use of regulated health products
3. Important Limitation: No General Inquiries or Status Queries
The advisory stresses that eSumbong is “not” a channel for general inquiries or following up on applications. Such submissions will be automatically rejected and not processed further, so the FDA can prioritize high-risk, high-priority reports.
-
Application status queries: use existing tracking tools such as the FDA eServices Portal, ePortal or the FDA Kiosk
-
General inquiries: send to the FDA’s official information email, info@fda.gov.ph
The FDA warns that misclassified reports may lead to delays in review or even automatic rejection, so companies and individuals should take care to choose the correct category.
4. How to Use It
-
Go to the eSumbong section of the FDA’s new website
-
Sign in with a Google account for identity verification – to ensure all reports are received securely, properly recorded and handled promptly
-
Select the category matching the content of your report from the five categories
-
After submission, the system automatically sends a confirmation email with a unique reference number; the relevant center/office then sends a formal acknowledgement with an internal Document Tracking Number (DTN) for follow-up
If the reporter chooses the wrong center, the center receiving the report is responsible for forwarding it to the correct unit so that it is properly handled and answered.
5. Practical Significance for Medical Device and IVD Companies
The launch of eSumbong gives the Philippine FDA a more structured mechanism for receiving and routing reports for market surveillance and enforcement. For medical device and in vitro diagnostic (IVD) companies, the main impacts are:
-
Consumer reporting channels are more transparent and convenient, so product quality and safety issues are more likely to be reported and noticed
-
Manufacturers and distributors may face closer scrutiny, objectively encouraging companies to take compliance standards more seriously
-
Maintaining clear post-market processes, distributor oversight mechanisms and adverse event documentation becomes even more important
-
We recommend that companies set up corresponding complaint response and record-keeping mechanisms so that, if reported or asked to cooperate with an investigation, they can promptly provide complete, documented evidence of compliance
Note: eSumbong is still being refined, and the email ereport@fda.gov.ph previously used for reporting safety issues such as counterfeit drugs is still mentioned in some official communications. Companies should refer to the latest announcements on the FDA website and watch for further functional extensions or channel changes.
If you need to review post-market compliance processes or distributor management for the Philippine market, or want to understand the potential impact of eSumbong on specific product lines, contact us – the EVERBIZ team will provide professional advice based on your situation.